I'm LongbridgeAI, I can summarize articles.SinoMab Bioscience Ltd. ( (HK:3681) ) has issued an update.
SinoMab BioScience has issued a supplemental announcement to its 2025 Annual Report, clarifying how it deployed funds raised from two share subscription exercises completed in May and July 2025 under a general mandate. The company confirmed that the net proceeds from both subscriptions were used in line with previously disclosed intentions, reinforcing its adherence to stated capital allocation plans and providing additional transparency for shareholders.
The company also elaborated on its share-based incentives, stating that 1,220,000 awards under its Share Award Scheme vested during the reporting period and are classified as share options under relevant accounting standards. Of these, 85,000 options were exercised at HK$1.12 per share, with a weighted average closing price of HK$1.69 before exercise, while the rest of the annual report remains unchanged, indicating no broader revisions to its previously reported financials or governance disclosures.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong-incorporated biopharmaceutical company listed on the Stock Exchange of Hong Kong, focusing on the research, development and commercialization of innovative biologic therapies. The company operates in the biotechnology and life sciences sector and funds its pipeline and operations through equity financing and share-based incentive schemes.
Average Trading Volume: 1,585,659
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.55B
For a thorough assessment of 3681 stock, go to TipRanks’ Stock Analysis page.
